Global Biologics and Biosimilars Market Outlook 2022

Global Biologics and Biosimilars Market Outlook 2022

Table of Contents
1 Biologics and Biosimilars Market Overview
1.1 Product Overview and Scope of Biologics and Biosimilars
1.2 Biologics and Biosimilars Segment by Type
1.2.1 Global Biologics and Biosimilars Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Biologics and Biosimilars Segment by Application
1.3.1 Global Biologics and Biosimilars Sales Comparison by Application: (2021-2027)
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Global Biologics and Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Biologics and Biosimilars Revenue 2016-2027
1.4.2 Global Biologics and Biosimilars Sales 2016-2027
1.4.3 Biologics and Biosimilars Market Size by Region: 2016 Versus 2021 Versus 2027
2 Biologics and Biosimilars Market Competition by Manufacturers
2.1 Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
2.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biologics and Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biologics and Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Biologics and Biosimilars Market Competitive Situation and Trends
2.5.1 Biologics and Biosimilars Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Biologics and Biosimilars Players Market Share by Revenue
2.5.3 Global Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Biologics and Biosimilars Retrospective Market Scenario by Region
3.1 Global Biologics and Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Biologics and Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Biologics and Biosimilars Market Facts & Figures by Country
3.3.1 North America Biologics and Biosimilars Sales by Country
3.3.2 North America Biologics and Biosimilars Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Biologics and Biosimilars Market Facts & Figures by Country
3.4.1 Europe Biologics and Biosimilars Sales by Country
3.4.2 Europe Biologics and Biosimilars Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Biologics and Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Biologics and Biosimilars Sales by Region
3.5.2 Asia Pacific Biologics and Biosimilars Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Biologics and Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Biologics and Biosimilars Sales by Country
3.6.2 Latin America Biologics and Biosimilars Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Biologics and Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Biologics and Biosimilars Sales by Country
3.7.2 Middle East and Africa Biologics and Biosimilars Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Biologics and Biosimilars Historic Market Analysis by Type
4.1 Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
4.2 Global Biologics and Biosimilars Revenue Market Share by Type (2016-2021)
4.3 Global Biologics and Biosimilars Price by Type (2016-2021)
5 Global Biologics and Biosimilars Historic Market Analysis by Application
5.1 Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
5.2 Global Biologics and Biosimilars Revenue Market Share by Application (2016-2021)
5.3 Global Biologics and Biosimilars Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Corporation Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Roche Biologics and Biosimilars Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Amgen Biologics and Biosimilars Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 AbbVie
6.3.1 AbbVie Corporation Information
6.3.2 AbbVie Description and Business Overview
6.3.3 AbbVie Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.3.4 AbbVie Biologics and Biosimilars Product Portfolio
6.3.5 AbbVie Recent Developments/Updates
6.4 Sanofi-Aventis
6.4.1 Sanofi-Aventis Corporation Information
6.4.2 Sanofi-Aventis Description and Business Overview
6.4.3 Sanofi-Aventis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Sanofi-Aventis Biologics and Biosimilars Product Portfolio
6.4.5 Sanofi-Aventis Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Novo Nordisk
6.6.1 Novo Nordisk Corporation Information
6.6.2 Novo Nordisk Description and Business Overview
6.6.3 Novo Nordisk Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
6.7.5 Novo Nordisk Recent Developments/Updates
6.8 Eli Lilly
6.8.1 Eli Lilly Corporation Information
6.8.2 Eli Lilly Description and Business Overview
6.8.3 Eli Lilly Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Eli Lilly Biologics and Biosimilars Product Portfolio
6.8.5 Eli Lilly Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Novartis Biologics and Biosimilars Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 Merck
6.10.1 Merck Corporation Information
6.10.2 Merck Description and Business Overview
6.10.3 Merck Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Merck Biologics and Biosimilars Product Portfolio
6.10.5 Merck Recent Developments/Updates
6.11 3sbio
6.11.1 3sbio Corporation Information
6.11.2 3sbio Biologics and Biosimilars Description and Business Overview
6.11.3 3sbio Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.11.4 3sbio Biologics and Biosimilars Product Portfolio
6.11.5 3sbio Recent Developments/Updates
6.12 Changchun High Tech
6.12.1 Changchun High Tech Corporation Information
6.12.2 Changchun High Tech Biologics and Biosimilars Description and Business Overview
6.12.3 Changchun High Tech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
6.12.5 Changchun High Tech Recent Developments/Updates
6.13 CP Guojian
6.13.1 CP Guojian Corporation Information
6.13.2 CP Guojian Biologics and Biosimilars Description and Business Overview
6.13.3 CP Guojian Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.13.4 CP Guojian Biologics and Biosimilars Product Portfolio
6.13.5 CP Guojian Recent Developments/Updates
6.14 Biotech
6.14.1 Biotech Corporation Information
6.14.2 Biotech Biologics and Biosimilars Description and Business Overview
6.14.3 Biotech Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Biotech Biologics and Biosimilars Product Portfolio
6.14.5 Biotech Recent Developments/Updates
6.15 Gelgen
6.15.1 Gelgen Corporation Information
6.15.2 Gelgen Biologics and Biosimilars Description and Business Overview
6.15.3 Gelgen Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Gelgen Biologics and Biosimilars Product Portfolio
6.15.5 Gelgen Recent Developments/Updates
6.16 Innovent
6.16.1 Innovent Corporation Information
6.16.2 Innovent Biologics and Biosimilars Description and Business Overview
6.16.3 Innovent Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Innovent Biologics and Biosimilars Product Portfolio
6.16.5 Innovent Recent Developments/Updates
6.17 Dong Bao
6.17.1 Dong Bao Corporation Information
6.17.2 Dong Bao Biologics and Biosimilars Description and Business Overview
6.17.3 Dong Bao Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.17.4 Dong Bao Biologics and Biosimilars Product Portfolio
6.17.5 Dong Bao Recent Developments/Updates
6.18 Ganlee
6.18.1 Ganlee Corporation Information
6.18.2 Ganlee Biologics and Biosimilars Description and Business Overview
6.18.3 Ganlee Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.18.4 Ganlee Biologics and Biosimilars Product Portfolio
6.18.5 Ganlee Recent Developments/Updates
6.19 United Laboratories
6.19.1 United Laboratories Corporation Information
6.19.2 United Laboratories Biologics and Biosimilars Description and Business Overview
6.19.3 United Laboratories Biologics and Biosimilars Sales, Revenue and Gross Margin (2016-2021)
6.19.4 United Laboratories Biologics and Biosimilars Product Portfolio
6.19.5 United Laboratories Recent Developments/Updates
7 Biologics and Biosimilars Manufacturing Cost Analysis
7.1 Biologics and Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Biologics and Biosimilars
7.4 Biologics and Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Biologics and Biosimilars Distributors List
8.3 Biologics and Biosimilars Customers
9 Biologics and Biosimilars Market Dynamics
9.1 Biologics and Biosimilars Industry Trends
9.2 Biologics and Biosimilars Growth Drivers
9.3 Biologics and Biosimilars Market Challenges
9.4 Biologics and Biosimilars Market Restraints
10 Global Market Forecast
10.1 Biologics and Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Biologics and Biosimilars by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Biologics and Biosimilars by Type (2022-2027)
10.2 Biologics and Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Biologics and Biosimilars by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Biologics and Biosimilars by Application (2022-2027)
10.3 Biologics and Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Biologics and Biosimilars by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Biologics and Biosimilars by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Biologics and Biosimilars Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Biologics and Biosimilars Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Biologics and Biosimilars Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Biologics and Biosimilars Covered in This Study
Table 5. Global Biologics and Biosimilars Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Biologics and Biosimilars Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Biologics and Biosimilars Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Biologics and Biosimilars Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Biologics and Biosimilars Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Biologics and Biosimilars Manufacturing Sites and Area Served
Table 11. Manufacturers Biologics and Biosimilars Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Biologics and Biosimilars as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Biologics and Biosimilars Sales by Region (2016-2021) & (K Units)
Table 16. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 17. Global Biologics and Biosimilars Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 19. North America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 20. North America Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 22. Europe Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 23. Europe Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 24. Europe Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Biologics and Biosimilars Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Biologics and Biosimilars Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Table 30. Latin America Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 32. Latin America Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Biologics and Biosimilars Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Biologics and Biosimilars Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Biologics and Biosimilars Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Biologics and Biosimilars Revenue Market Share by Country (2016-2021)
Table 38. Global Biologics and Biosimilars Sales (K Units) by Type (2016-2021)
Table 39. Global Biologics and Biosimilars Sales Market Share by Type (2016-2021)
Table 40. Global Biologics and Biosimilars Revenue (Million US$) by Type (2016-2021)
Table 41. Global Biologics and Biosimilars Revenue Share by Type (2016-2021)
Table 42. Global Biologics and Biosimilars Price (USD/Unit) by Type (2016-2021)
Table 43. Global Biologics and Biosimilars Sales (K Units) by Application (2016-2021)
Table 44. Global Biologics and Biosimilars Sales Market Share by Application (2016-2021)
Table 45. Global Biologics and Biosimilars Revenue (Million US$) by Application (2016-2021)
Table 46. Global Biologics and Biosimilars Revenue Share by Application (2016-2021)
Table 47. Global Biologics and Biosimilars Price (USD/Unit) by Application (2016-2021)
Table 48. Roche Corporation Information
Table 49. Roche Description and Business Overview
Table 50. Roche Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Roche Biologics and Biosimilars Product
Table 52. Roche Recent Developments/Updates
Table 53. Amgen Corporation Information
Table 54. Amgen Description and Business Overview
Table 55. Amgen Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Amgen Biologics and Biosimilars Product
Table 57. Amgen Recent Developments/Updates
Table 58. AbbVie Corporation Information
Table 59. AbbVie Description and Business Overview
Table 60. AbbVie Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. AbbVie Biologics and Biosimilars Product
Table 62. AbbVie Recent Developments/Updates
Table 63. Sanofi-Aventis Corporation Information
Table 64. Sanofi-Aventis Description and Business Overview
Table 65. Sanofi-Aventis Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Sanofi-Aventis Biologics and Biosimilars Product
Table 67. Sanofi-Aventis Recent Developments/Updates
Table 68. Johnson & Johnson Corporation Information
Table 69. Johnson & Johnson Description and Business Overview
Table 70. Johnson & Johnson Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Johnson & Johnson Biologics and Biosimilars Product
Table 72. Johnson & Johnson Recent Developments/Updates
Table 73. Pfizer Corporation Information
Table 74. Pfizer Description and Business Overview
Table 75. Pfizer Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Pfizer Biologics and Biosimilars Product
Table 77. Pfizer Recent Developments/Updates
Table 78. Novo Nordisk Corporation Information
Table 79. Novo Nordisk Description and Business Overview
Table 80. Novo Nordisk Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Novo Nordisk Biologics and Biosimilars Product
Table 82. Novo Nordisk Recent Developments/Updates
Table 83. Eli Lilly Corporation Information
Table 84. Eli Lilly Description and Business Overview
Table 85. Eli Lilly Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Eli Lilly Biologics and Biosimilars Product
Table 87. Eli Lilly Recent Developments/Updates
Table 88. Novartis Corporation Information
Table 89. Novartis Description and Business Overview
Table 90. Novartis Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Novartis Biologics and Biosimilars Product
Table 92. Novartis Recent Developments/Updates
Table 93. Merck Corporation Information
Table 94. Merck Description and Business Overview
Table 95. Merck Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Merck Biologics and Biosimilars Product
Table 97. Merck Recent Developments/Updates
Table 98. 3sbio Corporation Information
Table 99. 3sbio Description and Business Overview
Table 100. 3sbio Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. 3sbio Biologics and Biosimilars Product
Table 102. 3sbio Recent Developments/Updates
Table 103. Changchun High Tech Corporation Information
Table 104. Changchun High Tech Description and Business Overview
Table 105. Changchun High Tech Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. Changchun High Tech Biologics and Biosimilars Product
Table 107. Changchun High Tech Recent Developments/Updates
Table 108. CP Guojian Corporation Information
Table 109. CP Guojian Description and Business Overview
Table 110. CP Guojian Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. CP Guojian Biologics and Biosimilars Product
Table 112. CP Guojian Recent Developments/Updates
Table 113. Biotech Corporation Information
Table 114. Biotech Description and Business Overview
Table 115. Biotech Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Biotech Biologics and Biosimilars Product
Table 117. Biotech Recent Developments/Updates
Table 118. Gelgen Corporation Information
Table 119. Gelgen Description and Business Overview
Table 120. Gelgen Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. Gelgen Biologics and Biosimilars Product
Table 122. Gelgen Recent Developments/Updates
Table 123. Innovent Corporation Information
Table 124. Innovent Description and Business Overview
Table 125. Innovent Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Innovent Biologics and Biosimilars Product
Table 127. Innovent Recent Developments/Updates
Table 128. Dong Bao Corporation Information
Table 129. Dong Bao Description and Business Overview
Table 130. Dong Bao Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 131. Dong Bao Biologics and Biosimilars Product
Table 132. Dong Bao Recent Developments/Updates
Table 133. Ganlee Corporation Information
Table 134. Ganlee Description and Business Overview
Table 135. Ganlee Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 136. Ganlee Biologics and Biosimilars Product
Table 137. Ganlee Recent Developments/Updates
Table 138. United Laboratories Corporation Information
Table 139. United Laboratories Description and Business Overview
Table 140. United Laboratories Biologics and Biosimilars Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 141. United Laboratories Biologics and Biosimilars Product
Table 142. United Laboratories Recent Developments/Updates
Table 143. Production Base and Market Concentration Rate of Raw Material
Table 144. Key Suppliers of Raw Materials
Table 145. Biologics and Biosimilars Distributors List
Table 146. Biologics and Biosimilars Customers List
Table 147. Biologics and Biosimilars Market Trends
Table 148. Biologics and Biosimilars Growth Drivers
Table 149. Biologics and Biosimilars Market Challenges
Table 150. Biologics and Biosimilars Market Restraints
Table 151. Global Biologics and Biosimilars Sales Forecast by Type (2022-2027) & (K Units)
Table 152. Global Biologics and Biosimilars Sales Market Share Forecast by Type (2022-2027)
Table 153. Global Biologics and Biosimilars Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 154. Global Biologics and Biosimilars Revenue Market Share Forecast by Type (2022-2027)
Table 155. Global Biologics and Biosimilars Sales Forecast by Application (2022-2027) & (K Units)
Table 156. Global Biologics and Biosimilars Sales Market Share Forecast by Application (2022-2027)
Table 157. Global Biologics and Biosimilars Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 158. Global Biologics and Biosimilars Revenue Market Share Forecast by Application (2022-2027)
Table 159. Global Biologics and Biosimilars Sales Forecast by Region (2022-2027) & (K Units)
Table 160. Global Biologics and Biosimilars Sales Market Share Forecast by Region (2022-2027)
Table 161. Global Biologics and Biosimilars Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 162. Global Biologics and Biosimilars Revenue Market Share Forecast by Region (2022-2027)
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Biologics and Biosimilars
Figure 2. Global Biologics and Biosimilars Market Share by Type in 2020 & 2027
Figure 3. Monoclonal Antibodies Product Picture
Figure 4. Interferon Product Picture
Figure 5. Erythropoietin Product Picture
Figure 6. Insulin Product Picture
Figure 7. Vaccines Product Picture
Figure 8. Others Product Picture
Figure 9. Global Biologics and Biosimilars Market Share by Application in 2020 & 2027
Figure 10. Tumor
Figure 11. Diabetes
Figure 12. Cardiovascular
Figure 13. Hemophilia
Figure 14. Others
Figure 15. Global Biologics and Biosimilars Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Biologics and Biosimilars Market Size 2016-2027 (US$ Million)
Figure 17. Global Biologics and Biosimilars Sales 2016-2027 (K Units)
Figure 18. Global Biologics and Biosimilars Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 19. Biologics and Biosimilars Sales Share by Manufacturers in 2020
Figure 20. Global Biologics and Biosimilars Revenue Share by Manufacturers in 2020
Figure 21. The Global 5 and 10 Largest Biologics and Biosimilars Players: Market Share by Revenue in 2020
Figure 22. Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 23. Global Biologics and Biosimilars Sales Market Share by Region (2016-2021)
Figure 24. Global Biologics and Biosimilars Sales Market Share by Region in 2020
Figure 25. Global Biologics and Biosimilars Revenue Market Share by Region (2016-2021)
Figure 26. Global Biologics and Biosimilars Revenue Market Share by Region in 2020
Figure 27. U.S. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Canada Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Germany Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. France Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. U.K. Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Italy Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Russia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. China Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Japan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. South Korea Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. India Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Australia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Taiwan Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Indonesia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Thailand Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Malaysia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Philippines Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Vietnam Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Mexico Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Brazil Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Argentina Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Turkey Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 49. Saudi Arabia Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 50. U.A.E Biologics and Biosimilars Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. Sales Market Share of Biologics and Biosimilars by Type (2016-2021)
Figure 52. Sales Market Share of Biologics and Biosimilars by Application (2016-2021)
Figure 53. Sales Market Share of Biologics and Biosimilars by Application in 2020
Figure 54. Revenue Share of Biologics and Biosimilars by Application (2016-2021)
Figure 55. Revenue Share of Biologics and Biosimilars by Application in 2020
Figure 56. Manufacturing Cost Structure of Biologics and Biosimilars
Figure 57. Manufacturing Process Analysis of Biologics and Biosimilars
Figure 58. Biologics and Biosimilars Industrial Chain Analysis
Figure 59. Channels of Distribution
Figure 60. Distributors Profiles
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Biologics and Biosimilars Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 147

According to our LPI (LP Information) latest study, the global Biologics and Biosimilars market size was valued at US$ 458090 million in 2023. With growing demand in downstream market, the Biologics and Biosimilars is forecast to a readjusted size of US$ 837640 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Biologics and Biosimilars market. Biologics and Biosimilars are expected to show stable growth in the futu......

Global Biosimilar Drug Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94

According to our LPI (LP Information) latest study, the global Biosimilar Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Biosimilar Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Biosimilar Drug market. Biosimilar Drug are expected to show stable growth in the future market. However, product differentiation, reducing cost......

Global Biologics and Biosimilars Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 147

According to our (Global Info Research) latest study, the global Biologics and Biosimilars market size was valued at USD 481830 million in 2023 and is forecast to a readjusted size of USD 842330 million by 2030 with a CAGR of 8.3% during review period. Biologics are very specific, highly effective medicines made in living cells, and historically this was often an animal. Biologics include hormones, cytokines, growth factors, vaccines, gene and cellular therapies, fusion proteins, insulin......

Global Biosimilars Market Research Report 2023, Forecast to 2028

Published: 27-Dec-2023        Price: US 2680 Onwards        Pages: 167

A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......

Global Biosimilars Professional Survey Report 2023, Forecast to 2028

Published: 27-Dec-2023        Price: US 3280 Onwards        Pages: 133

A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technol......

Global Biosimilars Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 106

Market Overview of Global Biosimilars market: According to our latest research, the global Biosimilars market looks promising in the next 5 years. As of 2022, the global Biosimilars market was estimated at USD 8203.97 million, and it's anticipated to reach USD 40650.01 million in 2028, with a CAGR of 30.57% during the forecast years. A biosimilar product is a biologic product that is approved based on demonstrating that it is highly similar to an FDA?approved biologic product......

Global Biologics and Biosimilars Professional Survey Report 2023, Forecast to 2028

Published: 24-Nov-2023        Price: US 3280 Onwards        Pages: 134

Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......

Global Biologics and Biosimilars Market Research Report 2023, Forecast to 2028

Published: 24-Nov-2023        Price: US 2680 Onwards        Pages: 160

Biologics include a wide variety of products such as gene and cell therapies, therapeutic proteins, monoclonal antibodies, and vaccines. Biosimilars are highly similar to the reference product in terms of safety, purity and potency, but may have minor differences in clinically inactive components. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) da......

Global Biosimilar Monoclonal Antibodies Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 103

Market Overview of Global Biosimilar Monoclonal Antibodies market: According to our latest research, the global Biosimilar Monoclonal Antibodies market looks promising in the next 5 years. As of 2022, the global Biosimilar Monoclonal Antibodies market was estimated at USD 5156.19 million, and it's anticipated to reach USD 14274.14 million in 2028, with a CAGR of 18.5% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs